Connection

VINCENT TAM to Time Factors

This is a "connection" page, showing publications VINCENT TAM has written about Time Factors.
Connection Strength

0.581
  1. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64.
    View in: PubMed
    Score: 0.053
  2. Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther. 2013 Aug; 11(8):831-7.
    View in: PubMed
    Score: 0.053
  3. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9.
    View in: PubMed
    Score: 0.049
  4. Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother. 2012 Apr; 67(4):928-32.
    View in: PubMed
    Score: 0.047
  5. Optimizing dosage to prevent emergence of resistance - lessons from in vitro models. Curr Opin Pharmacol. 2011 Oct; 11(5):453-6.
    View in: PubMed
    Score: 0.046
  6. Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. J Antimicrob Chemother. 2011 May; 66(5):1079-86.
    View in: PubMed
    Score: 0.045
  7. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010 Aug; 10(4):441-51.
    View in: PubMed
    Score: 0.043
  8. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 degrees C. Am J Health Syst Pharm. 2010 Jul 15; 67(14):1191-4.
    View in: PubMed
    Score: 0.043
  9. Killing of Escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis. 2009 Jun; 64(2):166-71.
    View in: PubMed
    Score: 0.039
  10. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb; 60(2):163-7.
    View in: PubMed
    Score: 0.035
  11. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis. 2007 Jun 15; 195(12):1818-27.
    View in: PubMed
    Score: 0.034
  12. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother. 2007 Feb; 51(2):744-7.
    View in: PubMed
    Score: 0.033
  13. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006 Aug; 50(8):2626-31.
    View in: PubMed
    Score: 0.032
  14. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. J Antimicrob Chemother. 2015 Mar; 70(3):877-81.
    View in: PubMed
    Score: 0.014
  15. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006 Mar; 54(3):223-30.
    View in: PubMed
    Score: 0.008
  16. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003 Jul; 112(2):275-85.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.